Mounjaro weight loss eligibility: what the evidence and UK guidance say

What the NICE guidance and trial data say about who qualifies

NICE's appraisal of tirzepatide (TA1026) was built on evidence from the SURMOUNT clinical programme, which enrolled thousands of adults with obesity across multiple countries. The trials showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks, among the largest weight-loss figures ever recorded in a phase 3 medicines trial. That evidence base is what persuaded NICE to recommend tirzepatide for NHS use in eligible adults.

For NHS prescribing, NICE set the threshold at a BMI of 35 or above plus at least one weight-related comorbidity. The list of qualifying conditions includes type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. NHS access is being phased in gradually by cohort, so even meeting those criteria does not guarantee an immediate appointment at your GP surgery. Private prescribing follows the medicine's licensed indication, which is broader: BMI ≥30, or ≥27 with a relevant weight-related condition.

BMI thresholds are adjusted downward by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, because excess weight tends to carry greater metabolic risk at lower BMI values in those groups. You can calculate your current BMI using the NHS BMI calculator, which gives you a starting point before a clinical consultation. For a deeper look at the specific numbers, the BMI criteria for Mounjaro page walks through each threshold in detail.

Conditions that can affect whether Mounjaro is suitable for you

Eligibility is not purely a BMI question. A prescriber also looks at your medical history for anything that would make tirzepatide unsuitable. People with a personal or close family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia type 2, are not candidates for this treatment. A history of pancreatitis or certain gastrointestinal conditions requires careful clinical discussion before prescribing can go ahead.

Current medicines matter too. Tirzepatide slows gastric emptying, which can affect how quickly oral medicines are absorbed. Women taking the contraceptive pill should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after any dose increase, because pill absorption may be reduced. If you take medicines for blood pressure or diabetes alongside Mounjaro, your prescriber will want to monitor how your doses interact as your weight changes.

Pregnancy, breastfeeding and trying to conceive are all situations where tirzepatide is not recommended. The medicine is also not licensed for under-18s. None of this is meant to be a reason to self-screen yourself out, it is exactly why a prescriber reviews everything before approving treatment. If you have questions about interactions, the page on taking other medicines alongside Mounjaro covers common examples, and our FAQs address many of the situations patients ask about most often.

NHS eligibility versus private eligibility: the practical difference

The NHS and private routes to Mounjaro use different eligibility thresholds, and it is worth being clear on the distinction. Under NICE TA1026, NHS commissioning targets the highest-need patients first: currently, adults with a BMI of 40 or above and four or more of the five qualifying conditions. A second cohort covering BMI 35–39.9 with four or more conditions was activated in June 2026, and further phases are planned through to 2027. GP practices can now prescribe under the new contract, but participation varies, some practices have started, others have not.

Private prescribing operates under the medicine's full licensed indication. That means a BMI of 30 or above, or 27 or above with a weight-related condition, is the starting point for clinical assessment, not just for the highest-need tier. For people who want a clear picture of whether they qualify before booking a consultation, our Mounjaro eligibility page sets out the private and NHS routes side by side. You can check any online pharmacy on the GPhC register before placing an order, it takes about 30 seconds.

Cost is a real factor. Private treatment prices have risen since Eli Lilly adjusted UK list prices in September 2025, and the context around Mounjaro pricing in the UK explains what those figures mean for patients. For many people the decision comes down to a straightforward question: wait for an NHS appointment that may be months away, or start privately now under the same clinical safeguards. Neither is wrong, it depends on your situation.

What happens at a clinical assessment with nume

At nume, the consultation is free and takes place online. You answer a structured health questionnaire, then a GPhC-registered Independent Prescriber reads your answers personally and the same day. There is no algorithm making the call. Identity is verified with photo ID, and weight is confirmed on a live video call, not taken on trust from a typed number. If you are transferring from another provider or requesting a dose increase, evidence of your current treatment is required before anything moves forward.

If the prescriber is satisfied that Mounjaro is clinically appropriate, treatment is dispatched the same day for orders placed before noon on a weekday. That timing matters more than people expect: if you order on a Monday after payday, your pen can arrive Tuesday morning, in plain unbranded packaging via DPD tracked delivery. There are no subscription commitments and every repeat order goes through the same clinical review, so your prescriber is seeing your progress, not just auto-approving a refill.

To understand the full process, the step-by-step guide to getting Mounjaro for weight loss covers what to expect from first consultation to delivery. If you are ready to check your own eligibility, the Mounjaro eligibility criteria page details exactly what our prescribers look at before approving treatment, start with a free consultation and get a clinical answer the same day.